NCT00792623View on ClinicalTrials.gov

Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 8, 2003

Primary Completion Date

September 10, 2007

Study Completion Date

September 10, 2007

Conditions
Varicella
Interventions
BIOLOGICAL

VarilrixTM

Subcutaneous injection, 2 doses, in the deltoid region of the non-dominant upper arm.

Trial Locations (3)

3002

GSK Investigational Site, East Melbourne

3004

GSK Investigational Site, Melbourne

3050

GSK Investigational Site, Melbourne

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00792623 - Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM). | Biotech Hunter | Biotech Hunter